BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 34732728)

  • 1. Longitudinal single-cell analysis of a myeloma mouse model identifies subclonal molecular programs associated with progression.
    Croucher DC; Richards LM; Tsofack SP; Waller D; Li Z; Wei EN; Huang XF; Chesi M; Bergsagel PL; Sebag M; Pugh TJ; Trudel S
    Nat Commun; 2021 Nov; 12(1):6322. PubMed ID: 34732728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Linking transcriptional and genetic tumor heterogeneity through allele analysis of single-cell RNA-seq data.
    Fan J; Lee HO; Lee S; Ryu DE; Lee S; Xue C; Kim SJ; Kim K; Barkas N; Park PJ; Park WY; Kharchenko PV
    Genome Res; 2018 Aug; 28(8):1217-1227. PubMed ID: 29898899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma.
    Ledergor G; Weiner A; Zada M; Wang SY; Cohen YC; Gatt ME; Snir N; Magen H; Koren-Michowitz M; Herzog-Tzarfati K; Keren-Shaul H; Bornstein C; Rotkopf R; Yofe I; David E; Yellapantula V; Kay S; Salai M; Ben Yehuda D; Nagler A; Shvidel L; Orr-Urtreger A; Halpern KB; Itzkovitz S; Landgren O; San-Miguel J; Paiva B; Keats JJ; Papaemmanuil E; Avivi I; Barbash GI; Tanay A; Amit I
    Nat Med; 2018 Dec; 24(12):1867-1876. PubMed ID: 30523328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.
    Bolli N; Avet-Loiseau H; Wedge DC; Van Loo P; Alexandrov LB; Martincorena I; Dawson KJ; Iorio F; Nik-Zainal S; Bignell GR; Hinton JW; Li Y; Tubio JM; McLaren S; O' Meara S; Butler AP; Teague JW; Mudie L; Anderson E; Rashid N; Tai YT; Shammas MA; Sperling AS; Fulciniti M; Richardson PG; Parmigiani G; Magrangeas F; Minvielle S; Moreau P; Attal M; Facon T; Futreal PA; Anderson KC; Campbell PJ; Munshi NC
    Nat Commun; 2014; 5():2997. PubMed ID: 24429703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors.
    Mitra AK; Mukherjee UK; Harding T; Jang JS; Stessman H; Li Y; Abyzov A; Jen J; Kumar S; Rajkumar V; Van Ness B
    Leukemia; 2016 May; 30(5):1094-102. PubMed ID: 26710886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma.
    Melchor L; Brioli A; Wardell CP; Murison A; Potter NE; Kaiser MF; Fryer RA; Johnson DC; Begum DB; Hulkki Wilson S; Vijayaraghavan G; Titley I; Cavo M; Davies FE; Walker BA; Morgan GJ
    Leukemia; 2014 Aug; 28(8):1705-15. PubMed ID: 24480973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deciphering the chronology of copy number alterations in Multiple Myeloma.
    Aktas Samur A; Minvielle S; Shammas M; Fulciniti M; Magrangeas F; Richardson PG; Moreau P; Attal M; Anderson KC; Parmigiani G; Avet-Loiseau H; Munshi NC; Samur MK
    Blood Cancer J; 2019 Mar; 9(4):39. PubMed ID: 30914633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability.
    Dutta AK; Fink JL; Grady JP; Morgan GJ; Mullighan CG; To LB; Hewett DR; Zannettino ACW
    Leukemia; 2019 Feb; 33(2):457-468. PubMed ID: 30046162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease.
    Dang M; Wang R; Lee HC; Patel KK; Becnel MR; Han G; Thomas SK; Hao D; Chu Y; Weber DM; Lin P; Lutter-Berka Z; Berrios Nolasco DA; Huang M; Bansal H; Song X; Zhang J; Futreal A; Moreno Rueda LY; Symer DE; Green MR; Rojas Hernandez CM; Kroll M; Afshar-Khargan V; Ndacayisaba LJ; Kuhn P; Neelapu SS; Orlowski RZ; Wang L; Manasanch EE
    Cancer Cell; 2023 Jun; 41(6):1032-1047.e4. PubMed ID: 37311413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.
    Lee HC; Wang H; Baladandayuthapani V; Lin H; He J; Jones RJ; Kuiatse I; Gu D; Wang Z; Ma W; Lim J; O'Brien S; Keats J; Yang J; Davis RE; Orlowski RZ
    Br J Haematol; 2017 Apr; 177(1):80-94. PubMed ID: 28369725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells.
    Fagerli UM; Ullrich K; Stühmer T; Holien T; Köchert K; Holt RU; Bruland O; Chatterjee M; Nogai H; Lenz G; Shaughnessy JD; Mathas S; Sundan A; Bargou RC; Dörken B; Børset M; Janz M
    Oncogene; 2011 Jul; 30(28):3198-206. PubMed ID: 21478911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A transgenic mouse model of plasma cell malignancy shows phenotypic, cytogenetic, and gene expression heterogeneity similar to human multiple myeloma.
    Boylan KL; Gosse MA; Staggs SE; Janz S; Grindle S; Kansas GS; Van Ness BG
    Cancer Res; 2007 May; 67(9):4069-78. PubMed ID: 17483317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Host-Derived Matrix Metalloproteinase-13 Activity Promotes Multiple Myeloma-Induced Osteolysis and Reduces Overall Survival.
    Lo CH; Shay G; McGuire JJ; Li T; Shain KH; Choi JY; Fuerst R; Roush WR; Knapinska AM; Fields GB; Lynch CC
    Cancer Res; 2021 May; 81(9):2415-2428. PubMed ID: 33526510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma.
    Zhao JJ; Chu ZB; Hu Y; Lin J; Wang Z; Jiang M; Chen M; Wang X; Kang Y; Zhou Y; Ni Chonghaile T; Johncilla ME; Tai YT; Cheng JQ; Letai A; Munshi NC; Anderson KC; Carrasco RD
    Cancer Res; 2015 Oct; 75(20):4384-4397. PubMed ID: 26249174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haplotype-aware analysis of somatic copy number variations from single-cell transcriptomes.
    Gao T; Soldatov R; Sarkar H; Kurkiewicz A; Biederstedt E; Loh PR; Kharchenko PV
    Nat Biotechnol; 2023 Mar; 41(3):417-426. PubMed ID: 36163550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGK Kinase Activity in Multiple Myeloma Cells Protects against ER Stress Apoptosis via a SEK-Dependent Mechanism.
    Hoang B; Shi Y; Frost PJ; Mysore V; Bardeleben C; Lichtenstein A
    Mol Cancer Res; 2016 Apr; 14(4):397-407. PubMed ID: 26869290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The genetic architecture of multiple myeloma.
    Morgan GJ; Walker BA; Davies FE
    Nat Rev Cancer; 2012 Apr; 12(5):335-48. PubMed ID: 22495321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression.
    Dutta-Simmons J; Zhang Y; Gorgun G; Gatt M; Mani M; Hideshima T; Takada K; Carlson NE; Carrasco DE; Tai YT; Raje N; Letai AG; Anderson KC; Carrasco DR
    Blood; 2009 Sep; 114(13):2699-708. PubMed ID: 19652203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MNK kinases facilitate c-myc IRES activity in rapamycin-treated multiple myeloma cells.
    Shi Y; Frost P; Hoang B; Yang Y; Fukunaga R; Gera J; Lichtenstein A
    Oncogene; 2013 Jan; 32(2):190-7. PubMed ID: 22370634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TPL2 kinase regulates the inflammatory milieu of the myeloma niche.
    Hope C; Ollar SJ; Heninger E; Hebron E; Jensen JL; Kim J; Maroulakou I; Miyamoto S; Leith C; Yang DT; Callander N; Hematti P; Chesi M; Bergsagel PL; Asimakopoulos F
    Blood; 2014 May; 123(21):3305-15. PubMed ID: 24723682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.